Cargando…

Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol

Patients with Marfan syndrome (MFS) develop thoracic aortic aneurysms as the aorta presents excessive elastin breaks, fibrosis, and vascular smooth muscle cell (vSMC) death due to mutations in the FBN1 gene. Despite elaborate vSMC to aortic endothelial cell (EC) signaling, the contribution of ECs to...

Descripción completa

Detalles Bibliográficos
Autores principales: Mieremet, Arnout, van der Stoel, Miesje, Li, Siyu, Coskun, Evrim, van Krimpen, Tsveta, Huveneers, Stephan, de Waard, Vivian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797556/
https://www.ncbi.nlm.nih.gov/pubmed/36577770
http://dx.doi.org/10.1038/s41598-022-26662-5
_version_ 1784860707718692864
author Mieremet, Arnout
van der Stoel, Miesje
Li, Siyu
Coskun, Evrim
van Krimpen, Tsveta
Huveneers, Stephan
de Waard, Vivian
author_facet Mieremet, Arnout
van der Stoel, Miesje
Li, Siyu
Coskun, Evrim
van Krimpen, Tsveta
Huveneers, Stephan
de Waard, Vivian
author_sort Mieremet, Arnout
collection PubMed
description Patients with Marfan syndrome (MFS) develop thoracic aortic aneurysms as the aorta presents excessive elastin breaks, fibrosis, and vascular smooth muscle cell (vSMC) death due to mutations in the FBN1 gene. Despite elaborate vSMC to aortic endothelial cell (EC) signaling, the contribution of ECs to the development of aortic pathology remains largely unresolved. The aim of this study is to investigate the EC properties in Fbn1(C1041G/+) MFS mice. Using en face immunofluorescence confocal microscopy, we showed that EC alignment with blood flow was reduced, EC roundness was increased, individual EC surface area was larger, and EC junctional linearity was decreased in aortae of Fbn1(C1041G/+) MFS mice. This modified EC phenotype was most prominent in the ascending aorta and occurred before aortic dilatation. To reverse EC morphology, we performed treatment with resveratrol. This restored EC blood flow alignment, junctional linearity, phospho-eNOS expression, and improved the structural integrity of the internal elastic lamina of Fbn1(C1041G/+) mice. In conclusion, these experiments identify the involvement of ECs and underlying internal elastic lamina in MFS aortic pathology, which could act as potential target for future MFS pharmacotherapies.
format Online
Article
Text
id pubmed-9797556
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-97975562022-12-30 Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol Mieremet, Arnout van der Stoel, Miesje Li, Siyu Coskun, Evrim van Krimpen, Tsveta Huveneers, Stephan de Waard, Vivian Sci Rep Article Patients with Marfan syndrome (MFS) develop thoracic aortic aneurysms as the aorta presents excessive elastin breaks, fibrosis, and vascular smooth muscle cell (vSMC) death due to mutations in the FBN1 gene. Despite elaborate vSMC to aortic endothelial cell (EC) signaling, the contribution of ECs to the development of aortic pathology remains largely unresolved. The aim of this study is to investigate the EC properties in Fbn1(C1041G/+) MFS mice. Using en face immunofluorescence confocal microscopy, we showed that EC alignment with blood flow was reduced, EC roundness was increased, individual EC surface area was larger, and EC junctional linearity was decreased in aortae of Fbn1(C1041G/+) MFS mice. This modified EC phenotype was most prominent in the ascending aorta and occurred before aortic dilatation. To reverse EC morphology, we performed treatment with resveratrol. This restored EC blood flow alignment, junctional linearity, phospho-eNOS expression, and improved the structural integrity of the internal elastic lamina of Fbn1(C1041G/+) mice. In conclusion, these experiments identify the involvement of ECs and underlying internal elastic lamina in MFS aortic pathology, which could act as potential target for future MFS pharmacotherapies. Nature Publishing Group UK 2022-12-28 /pmc/articles/PMC9797556/ /pubmed/36577770 http://dx.doi.org/10.1038/s41598-022-26662-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Mieremet, Arnout
van der Stoel, Miesje
Li, Siyu
Coskun, Evrim
van Krimpen, Tsveta
Huveneers, Stephan
de Waard, Vivian
Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol
title Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol
title_full Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol
title_fullStr Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol
title_full_unstemmed Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol
title_short Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol
title_sort endothelial dysfunction in marfan syndrome mice is restored by resveratrol
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797556/
https://www.ncbi.nlm.nih.gov/pubmed/36577770
http://dx.doi.org/10.1038/s41598-022-26662-5
work_keys_str_mv AT mieremetarnout endothelialdysfunctioninmarfansyndromemiceisrestoredbyresveratrol
AT vanderstoelmiesje endothelialdysfunctioninmarfansyndromemiceisrestoredbyresveratrol
AT lisiyu endothelialdysfunctioninmarfansyndromemiceisrestoredbyresveratrol
AT coskunevrim endothelialdysfunctioninmarfansyndromemiceisrestoredbyresveratrol
AT vankrimpentsveta endothelialdysfunctioninmarfansyndromemiceisrestoredbyresveratrol
AT huveneersstephan endothelialdysfunctioninmarfansyndromemiceisrestoredbyresveratrol
AT dewaardvivian endothelialdysfunctioninmarfansyndromemiceisrestoredbyresveratrol